MA43283B1 - Composition pour le traitement du cancer - Google Patents

Composition pour le traitement du cancer

Info

Publication number
MA43283B1
MA43283B1 MA43283A MA43283A MA43283B1 MA 43283 B1 MA43283 B1 MA 43283B1 MA 43283 A MA43283 A MA 43283A MA 43283 A MA43283 A MA 43283A MA 43283 B1 MA43283 B1 MA 43283B1
Authority
MA
Morocco
Prior art keywords
peptide
cancer
expressing
administering
induction
Prior art date
Application number
MA43283A
Other languages
English (en)
Other versions
MA43283A (fr
Inventor
David A Scheinberg
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MA43283A publication Critical patent/MA43283A/fr
Publication of MA43283B1 publication Critical patent/MA43283B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001141—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des procédés de traitement, de réduction de l'incidence des réponses immunitaires et de leur induction vis-à-vis d'un cancer exprimant wt1, par l'administration d'une combinaison d'au moins un peptide wt1, ou de lymphocytes t cytotoxiques (ctl) contre un cancer exprimant wt1, et d'au moins un inhibiteur de point de contrôle. Ledit ou les lesdits peptides wt1 peuvent être administrés au sujet par administration d'un ou de plusieurs agents au sujet entraînant l'apport d'un ou plusieurs peptides wt1 et l'induction d'une réponse immunitaire contre le cancer exprimant wt1. Des exemples de ces agents d'administration wt1 comprennent : (i) un peptide wt1 isolé, (ii) un acide nucléique codant pour le ou les peptides wt1, et (iii) une cellule immunitaire comprenant ou présentant le ou les peptides wt1 ou un acide nucléique codant pour le ou les peptides wt1.
MA43283A 2015-11-20 2016-11-18 Composition pour le traitement du cancer MA43283B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562258134P 2015-11-20 2015-11-20
PCT/US2016/062865 WO2017087857A1 (fr) 2015-11-20 2016-11-18 Procédés et compositions pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA43283A MA43283A (fr) 2018-09-26
MA43283B1 true MA43283B1 (fr) 2022-08-31

Family

ID=58717878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43283A MA43283B1 (fr) 2015-11-20 2016-11-18 Composition pour le traitement du cancer

Country Status (20)

Country Link
US (1) US11033613B2 (fr)
EP (2) EP4130026A1 (fr)
JP (3) JP6991969B2 (fr)
KR (2) KR20250099263A (fr)
CN (4) CN108431022B (fr)
AU (2) AU2016356708B2 (fr)
CA (1) CA3005896C (fr)
DK (1) DK3377516T3 (fr)
ES (1) ES2926386T3 (fr)
HR (1) HRP20220994T1 (fr)
HU (1) HUE059694T2 (fr)
LT (1) LT3377516T (fr)
MA (1) MA43283B1 (fr)
MD (1) MD3377516T2 (fr)
PL (1) PL3377516T3 (fr)
PT (1) PT3377516T (fr)
RS (1) RS63561B1 (fr)
SI (1) SI3377516T1 (fr)
SM (1) SMT202200370T1 (fr)
WO (1) WO2017087857A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3117836A1 (fr) * 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Peptides wt-1 immunogènes et leurs utilisations
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
EP4130026A1 (fr) 2015-11-20 2023-02-08 Memorial Sloan-Kettering Cancer Center Procédés et compositions de traitement du cancer
JP7071288B2 (ja) 2016-05-18 2022-05-18 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
EP3468581A1 (fr) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Méthodes et procédés pour favoriser la fonction des cellules immunitaires
CN110506107A (zh) 2016-11-30 2019-11-26 阿德瓦希斯公司 靶向复发性癌症突变的免疫原性组合物及其使用方法
MX2019007611A (es) 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
EP3565829A4 (fr) 2017-01-09 2021-01-27 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
CN118453840A (zh) 2017-03-15 2024-08-09 库尔生物制药有限公司 用于调节免疫应答的方法
WO2019006401A2 (fr) * 2017-06-30 2019-01-03 Advaxis, Inc. Compositions immunogènes à base de listeria comprenant des antigènes de protéine tumorale de wilms hétéroclitique et procédés d'utilisation correspondants
EP3678701A4 (fr) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. Compositions protéiques thérapeutiques et procédés de préparation et d'utilisation de celles-ci
JP2021502083A (ja) * 2017-11-08 2021-01-28 アドバクシス， インコーポレイテッド がん関連タンパク質由来の免疫原性ヘテロクリティックペプチドおよびその使用の方法
WO2019139896A1 (fr) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
WO2019173499A1 (fr) * 2018-03-06 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-bêta-hydroxywithanolides et leur utilisation dans le traitement du cancer
JP7393752B2 (ja) * 2018-10-05 2023-12-07 株式会社癌免疫研究所 良性腫瘍の予防または治療薬
TWI856047B (zh) 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
MX2021012422A (es) * 2019-04-10 2022-01-19 Slsg Ltd Llc Composición de inmunoterapia multivalente y métodos para usarse en el tratamiento de cánceres positivos a la proteína del tumor de wilms 1 (wt1).
TWI895295B (zh) 2019-11-12 2025-09-01 美商方得生醫療公司 偵測編碼新生抗原之融合基因之方法
WO2021138447A1 (fr) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Administration transitoire basée sur la température d'acides nucléiques et de protéines à des cellules et des tissus
WO2021206831A1 (fr) * 2020-04-07 2021-10-14 Metanoi Therapeutics, Inc. Formulation d'éthanolamine pour le traitement du carcinome ovarien épithélial
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
JPH06505486A (ja) 1991-02-07 1994-06-23 モレキュメティクス，リミティド βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
AU7518194A (en) 1993-07-29 1995-02-28 Regents Of The University Of California, The Polynucleotide decoys that ihnibit mhc-ii expression and uses thereof
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
EP1103564B1 (fr) 1998-07-31 2009-01-07 International Institute of Cancer Immunology, Inc. Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
PL201881B1 (pl) * 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
AU7859900A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
KR101050703B1 (ko) 2002-06-12 2011-07-20 추가이 세이야쿠 가부시키가이샤 Ｈｌａ-ａ24-구속성 암 항원 펩티드
ES2443582T3 (es) 2003-06-27 2014-02-19 International Institute Of Cancer Immunology, Inc. Método para diagnosticar el cáncer que comprende la medición de las células precursoras de CTL específicos de WT1
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
US7488718B2 (en) 2003-12-01 2009-02-10 Sloan Kettering Institue For Cancer Research Synthetic HLA binding peptide analogues and uses thereof
US20060127409A1 (en) 2003-12-01 2006-06-15 Scheinberg David A Bcr-abl vaccines and methods of use thereof
WO2007047764A2 (fr) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Peptides de liaison wt1 hla de classe ii, compositions et methodes associees comprenant ces peptides
DE102006014261A1 (de) 2006-03-28 2007-10-04 Dr.Ing.H.C. F. Porsche Ag Luftleitvorrichtung für ein Fahrzeug
EP3117836A1 (fr) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Peptides wt-1 immunogènes et leurs utilisations
CA2940962C (fr) 2007-12-05 2018-07-24 International Institute Of Cancer Immunology, Inc. Composition de vaccin contre le cancer
US20110136141A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
HK1204261A1 (en) 2012-01-13 2015-11-13 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
CN103961702B (zh) * 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
MX369709B (es) 2013-03-15 2019-11-19 Univ Pennsylvania Vacunación mejorada contra tirosinasa.
WO2015061752A1 (fr) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Traitement à l'aide d'inhibiteurs de la tyrosine kinase de bruton et de l'immunothérapie
US20150273033A1 (en) 2013-11-05 2015-10-01 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
KR20220062143A (ko) * 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
CA2942501A1 (fr) * 2014-03-17 2015-09-24 Tapimmune Inc. Compositions vaccinales a molecules d'acide nucleique et leurs utilisations
JP6515182B2 (ja) * 2015-05-20 2019-05-15 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
EP4130026A1 (fr) 2015-11-20 2023-02-08 Memorial Sloan-Kettering Cancer Center Procédés et compositions de traitement du cancer

Also Published As

Publication number Publication date
KR102823333B1 (ko) 2025-06-23
CA3005896C (fr) 2025-09-23
PL3377516T3 (pl) 2022-10-10
RS63561B1 (sr) 2022-10-31
SMT202200370T1 (it) 2022-11-18
AU2016356708B2 (en) 2022-02-03
EP3377516A4 (fr) 2019-06-26
JP2024041809A (ja) 2024-03-27
CN115920017A (zh) 2023-04-07
EP3377516A1 (fr) 2018-09-26
AU2016356708A1 (en) 2018-07-05
CN108431022A (zh) 2018-08-21
CA3005896A1 (fr) 2017-05-26
US20180339030A1 (en) 2018-11-29
AU2022202973B2 (en) 2025-07-24
US11033613B2 (en) 2021-06-15
KR20250099263A (ko) 2025-07-01
JP6991969B2 (ja) 2022-03-03
ES2926386T3 (es) 2022-10-25
JP2022033926A (ja) 2022-03-02
CN116327902A (zh) 2023-06-27
MA43283A (fr) 2018-09-26
PT3377516T (pt) 2022-09-23
LT3377516T (lt) 2022-09-26
HUE059694T2 (hu) 2022-12-28
AU2022202973A1 (en) 2022-05-26
CN108431022B (zh) 2022-08-09
DK3377516T3 (da) 2022-09-19
SI3377516T1 (sl) 2023-01-31
CN116327903A (zh) 2023-06-27
JP2018538265A (ja) 2018-12-27
EP3377516B1 (fr) 2022-06-15
WO2017087857A1 (fr) 2017-05-26
EP4130026A1 (fr) 2023-02-08
KR20180094922A (ko) 2018-08-24
MD3377516T2 (ro) 2022-10-31
HRP20220994T1 (hr) 2022-11-11

Similar Documents

Publication Publication Date Title
MA43283B1 (fr) Composition pour le traitement du cancer
MA42020A1 (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers
MA42072A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre la cll et d'autres cancers
MA41879A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA43466A1 (fr) Traitements du cancer de l'utérus
MA43075A1 (fr) Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
MA42021A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon à petites cellules et d'autres cancers
MA38406A1 (fr) Virus de la maladie de newcastle et leurs utilisations
MA39390A1 (fr) Thérapie génique pour le traitement de la rétinite pigmentaire
MA43490A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA43327A1 (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et d'autres cancers
IN2014KN01713A (fr)
IN2014KN01714A (fr)
IN2014KN01716A (fr)
MA43461A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA41717A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
MA40813A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
MA41520B2 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA40713A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
MA42294B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
JP2017530130A5 (fr)
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal